Walden Group Healthcare M&A Blog

VasSol Ushers in a New Stroke Diagnostic Standard of Care

10/07/2015
The Journal of the American Medical Association - Neurology (JAMA Neurology) has indicated it will publish the results of the landmark stroke diagnostic study - VERiTAS (Vertebrobasilar Flow Evaluation and Risk of Transient Ischaemic Attack and Stroke study (VERiTAS). Acceptance by this highly prestigious and influential peer-reviewed journal...
Read More
Aesthetic Surgery Market Trends - 2015

09/29/2015
Key factors "shaping" the aesthetic surgery market and healthcare M&A activity in it are: Large and Growing Market 15.6 million cosmetic procedures, including both minimally-invasive and surgical, were performed in the US in 2014, an increase of 3% since 2013. Additionally, 5.8 million reconstructive surgery procedures were performed last...
Read More
Allergan buys AqueSys, a maker of minimally invasive glaucoma surgery products, for $300m+

09/17/2015
The deal provides Allergan with AqueSys's minimally invasive glaucoma surgery (MIGS) device called the XEN45 Gel Stent. MIGS devices are alternatives to glaucoma medication and more invasive surgical techniques. The leader in the MIGS area is Glaukos, which closed an IPO in June 2015 and now has a market cap of over $1b. Its iStent is...
Read More
Walden Group Arranges the sale of JoViPak Corporation to BSN Medical GmbH & Co. KG

09/09/2015
The Walden Group advised JoViPak Corporation and arranged for its sale to BSN Medical GmbH & Co. KG,, a $850m manufacturer of products for wound care, vascular disease, lymphology and non-invasive orthopaedic conditions. JoViPak pioneered the market for night-time lymphedema garments to manage lymphatic disorders, an underserved, yet...
Read More
Drugs for Rare Diseases, Cancer and other Conditions Continue to Enjoy High Pricing, but For How Long?

09/01/2015
The recent $3.2b healthcare M&A purchase of Synageva BioPharma Corp. by Alexion Pharmaceuticals again put the spotlight on the high cost of specialty drugs. Synageva's lead candidate, Kanuma, is designed to treat lysosomal acid lipase deficiency, a genetic disease in which people do not produce enough of a certain enzyme. Infants with...
Read More